Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke

Reperfusion therapy with tissue plasminogen activator (tPA) is a rational therapy for acute ischemic stroke. Properly titrated use of tPA improves clinical outcomes. However, there is also an associated risk of hemorrhagic transformation after tPA therapy. Emerging data now suggest that some of these potentially neurotoxic side effects of tPA may be due to its signaling actions in the neurovascular unit. Besides its intended role in clot lysis, tPA is also an extracellular protease and signaling molecule in brain. tPA mediates matrix remodeling during brain development and plasticity. By interacting with the NMDA-type glutamate receptor, tPA may amplify potentially excitotoxic calcium currents. At selected concentrations, tPA may be vasoactive. Finally, by augmenting matrix metalloproteinase (MMP) dysregulation after stroke, tPA may degrade extracellular matrix integrity and increase risks of neurovascular cell death, blood–brain barrier leakage, edema, and hemorrhage. Understanding these pleiotropic actions of tPA may reveal new therapeutic opportunities for combination stroke therapy.

[1]  E. Lo,et al.  Induction of Caspase-Mediated Cell Death by Matrix Metalloproteinases in Cerebral Endothelial Cells after Hypoxia—Reoxygenation , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  T. Nabeshima,et al.  The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[4]  K. Bdeir,et al.  In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. , 2004, Blood.

[5]  M. Moskowitz,et al.  tPA and proteolysis in the neurovascular unit. , 2004, Stroke.

[6]  D. Lawrence,et al.  Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. , 2003, The Journal of clinical investigation.

[7]  J. Marler,et al.  Stroke--tPA and the Clinic , 2003, Science.

[8]  K. Arai,et al.  Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator , 2003, Nature Medicine.

[9]  K. Nicolay,et al.  Interferon-Beta Prevents Cytokine-Induced Neutrophil Infiltration and Attenuates Blood–Brain Barrier Disruption , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  J. Koziol,et al.  Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. , 2003, Stroke.

[11]  G. D. del Zoppo,et al.  Cerebral Microvessel Responses to Focal Ischemia , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  G. Rosenberg,et al.  Closure of the Blood-Brain Barrier by Matrix Metalloproteinase Inhibition Reduces rtPA-Mediated Mortality in Cerebral Ischemia With Delayed Reperfusion , 2003, Stroke.

[13]  J. M. Wardlaw,et al.  Thrombolytic Therapy With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke: Where Do We Go From Here? A Cumulative Meta-Analysis , 2003, Stroke.

[14]  Eng H. Lo,et al.  Neurological diseases: Mechanisms, challenges and opportunities in stroke , 2003, Nature Reviews Neuroscience.

[15]  J. Arenillas,et al.  Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke , 2003, Circulation.

[16]  R. Medcalf,et al.  Vampire Bat Salivary Plasminogen Activator (Desmoteplase): A Unique Fibrinolytic Enzyme That Does Not Promote Neurodegeneration , 2003, Stroke.

[17]  S. Strickland,et al.  Laminin chain expression suggests that laminin-10 is a major isoform in the mouse hippocampus and is degraded by the tissue plasminogen activator/plasmin protease cascade during excitotoxic injury , 2003, Neuroscience.

[18]  J. Serena,et al.  Plasma Metalloproteinase-9 Concentration Predicts Hemorrhagic Transformation in Acute Ischemic Stroke , 2003, Stroke.

[19]  E. Lo,et al.  Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9 Expression During Reperfusion Injury: Mechanical Versus Embolic Focal Ischemia in Spontaneously Hypertensive Rats , 2002, Stroke.

[20]  Reciprocal actions of NCAM and tPA via a Ras-dependent MAPK activation in rat hippocampal neurons. , 2002, Biochemical and biophysical research communications.

[21]  P. Lapchak,et al.  Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits , 2002, Stroke.

[22]  G. Rosenberg.  Matrix metalloproteinases in neuroinflammation , 2002, Glia.

[23]  M. Chopp,et al.  Adjuvant Treatment With Neuroserpin Increases the Therapeutic Window for Tissue-Type Plasminogen Activator Administration in a Rat Model of Embolic Stroke , 2002, Circulation.

[24]  Antonio Pisani,et al.  Tissue plasminogen activator is required for corticostriatal long‐term potentiation , 2002, The European journal of neuroscience.

[25]  C. Siao,et al.  Tissue Plasminogen Activator Mediates Microglial Activation via Its Finger Domain through Annexin II , 2002, The Journal of Neuroscience.

[26]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats , 2002, Stroke.

[27]  M. Fini,et al.  Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood–Brain Barrier and White Matter Components after Cerebral Ischemia , 2001, The Journal of Neuroscience.

[28]  D. Strickland,et al.  LRP: a multifunctional scavenger and signaling receptor. , 2001, The Journal of clinical investigation.

[29]  V. Wee Yong,et al.  Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.

[30]  N. Seeds,et al.  Mice Lacking tPA, uPA, or Plasminogen Genes Showed Delayed Functional Recovery after Sciatic Nerve Crush , 2001, The Journal of Neuroscience.

[31]  N. Seeds,et al.  Induction of the Plasminogen Activator System Accompanies Peripheral Nerve Regeneration after Sciatic Nerve Crush , 2001, The Journal of Neuroscience.

[32]  Alain Buisson,et al.  The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling , 2001, Nature Medicine.

[33]  M. Fini,et al.  Role for Matrix Metalloproteinase 9 after Focal Cerebral Ischemia: Effects of Gene Knockout and Enzyme Inhibition with BB-94 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  P. Lapchak,et al.  Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic Stroke , 2000, Stroke.

[35]  M. Fini,et al.  Effects of Matrix Metalloproteinase-9 Gene Knock-Out on Morphological and Motor Outcomes after Traumatic Brain Injury , 2000, The Journal of Neuroscience.

[36]  R. Ackerman,et al.  Effects of Tissue Type Plasminogen Activator in Embolic versus Mechanical Models of Focal Cerebral Ischemia in Rats , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  M. Basham,et al.  Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Dominique Muller,et al.  Enhanced hippocampal long‐term potentiation and learning by increased neuronal expression of tissue‐type plasminogen activator in transgenic mice , 1999, The EMBO journal.

[39]  A. Buchan,et al.  Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia , 1999, Neurology.

[40]  W. Hacke,et al.  Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. , 1999, Neurology.

[41]  S. Lipton,et al.  Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice , 1998, Nature Medicine.

[42]  H. Wada,et al.  Origin of patterning in neural tubes , 1996, Nature.

[43]  S. Tsirka,et al.  Neuronal cell death and tPA , 1996, Nature.

[44]  E. Kandel,et al.  Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[46]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[47]  A. Dibenedetto,et al.  Localization of tissue plasminogen activator mRNA in the developing rat cerebellum and effects of inhibiting tissue plasminogen activator on granule cell migration. , 1995, Journal of neurobiology.

[48]  W G Richards,et al.  The mouse tissue plasminogen activator gene 5' flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. , 1994, Development.

[49]  D. Belin,et al.  Extracellular proteolysis in the adult murine brain. , 1993, The Journal of clinical investigation.

[50]  Eric R. Kandel,et al.  Tissue-plasminogen activator is induced as an immediate–early gene during seizure, kindling and long-term potentiation , 1993, Nature.

[51]  D. Owen,et al.  The expression of tissue and urokinase-type plasminogen activators in neural development suggests different modes of proteolytic involvement in neuronal growth. , 1992, Development.